Experimental weight-loss drug outperforms original GLP-1s
An experimental weight-loss drug called GLP-1-GIP-Lani has shown promise in early trials conducted by Helmholtz Munich, outperforming traditional GLP-1-based treatments. The drug combines appetite and blood sugar-regulating hormones with PPAR activity to improve metabolic health. Researchers describe it as a 'Trojan horse' that may allow lower dosages and fewer side effects.
- ▪The drug GLP-1-GIP-Lani is a quintuple agonist targeting five receptor systems involved in metabolism.
- ▪It combines GLP-1 and GIP hormones with PPAR activity to enhance insulin sensitivity, fat metabolism, and reduce inflammation.
- ▪The drug was tested in mouse models with obesity, insulin resistance, and diabetes-induced metabolic conditions.
- ▪Researchers led by Professor Timo D. Muller at Helmholtz Munich believe the 'Trojan horse' mechanism enables targeted delivery and lower dosing.
- ▪The study was published in the journal Nature and based on preclinical research in animals.
Opening excerpt (first ~120 words) tap to expand
Health Experimental obesity drug outperforms traditional weight-loss treatments in early research Researchers call the compound a 'Trojan horse' that could allow for lower dosages and fewer side effects By Angelica Stabile Fox News Published May 14, 2026 7:00am EDT Facebook Twitter Threads Flipboard Comments Print Email Add Fox News on Google close Video Peptides can be useful, but some people may be moving too fast, expert warns New York fitness trainer and gym owner Kenny Santucci discusses concerns about unverified peptide products for muscle building, saying consumers should work with physicians. NEWYou can now listen to Fox News articles! A new weight-loss drug variation is showing promise in early trials.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fox News.
Discussion
0 commentsMore from Fox News
